<DOC>
	<DOCNO>NCT00594646</DOCNO>
	<brief_summary>This study evaluate safe tolerable combination take three-drugs purpose prevent HIV transmission high-risk sexual contact exposure HIV uninfected adult .</brief_summary>
	<brief_title>HIV Non Occupational Post-Exposure Prophylaxis ( PEP )</brief_title>
	<detailed_description>This study evaluate three drug regimen form two pill take 28 day prevention HIV infection . Two drug combine FDA-approved pill call TRUVADA , contain HIV medication , tenofovir disoproxil fumarate 300mg emtricitabine 200mg , take one pill day . The third drug new formulation , raltegravir 400mg pill take twice day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV uninfected basis negative HIV Rapid Test , EIA Western blot , negative HIV1 RNA assay Possible nonoccupational exposure HIV1 , recent enough permit receive first dose study medication within 72 hour end exposure . Able understand study procedure willing sign inform consent Any active psychiatric illness active drug alcohol abuse , opinion investigator , could prevent compliance study procedure . Pregnancy . Chronic hepatitis B infection , diagnose either positive serum HBsAg positive serum HBV DNA ; prior lamivudine therapy hepatitis B. Creatinine clearance le 50 mL/min calculate CockcroftGault formula . Unwillingness participate study procedure , include Mental Health referral intervention . Known intolerance allergy tenofovir DF , emtricitabine raltegravir . Use prohibit concomitant medication : dilantin , phenobarbital rifampin use raltegravir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HIV Prevention</keyword>
	<keyword>Non-occupational post-exposure prophylaxis</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>